Federal Hemp Ban: Policy Changes, CBD Impact, and Legal Implications

Executive Summary

A proposed federal hemp ban threatens to criminalize CBD products and upend a multi-billion dollar industry that has operated legally since the 2018 Farm Bill. The regulatory action, driven by concerns over intoxicating hemp-derived cannabinoids like delta-8 THC and THCA, could inadvertently sweep traditional CBD products into Schedule I controlled substance status. The ban would affect an estimated $28 billion hemp market, including CBD oils, topicals, and supplements used by millions of Americans for pain management, anxiety relief, and sleep support. The proposal has drawn opposition from hemp farmers, CBD manufacturers, consumer advocacy groups, and even Medicare administrators who had planned to incorporate CBD coverage into benefit packages. The Drug Enforcement Administration and Food and Drug Administration are currently reviewing public comments on the proposed rule, with a final decision expected in late 2026 or early 2027.

Why This Matters

The federal hemp ban would directly impact 17,000 hemp farmers, 10,000 CBD manufacturers, and an estimated 64 million American consumers who use CBD products regularly. The economic stakes extend beyond the hemp industry itself. Retail chains, health food stores, and online marketplaces have built entire business segments around CBD products since federal legalization in 2018. A sudden ban would force inventory liquidation, trigger breach-of-contract lawsuits, and potentially eliminate 150,000 jobs across cultivation, processing, retail, and distribution sectors.

For patients, the implications are particularly severe. Many Americans turned to CBD as an alternative to opioid pain medications or prescription anxiety drugs. Veterans groups have reported widespread CBD use among former service members managing PTSD and chronic pain. A ban would force these individuals back to pharmaceutical options or into state-legal cannabis markets where available. In states without adult-use cannabis programs, patients would lose legal access entirely.

The Medicare angle adds another layer of complexity. The Centers for Medicare & Medicaid Services had been developing a pilot program to cover CBD products for chronic pain management in seniors, viewing it as a potential tool to reduce opioid prescriptions among elderly beneficiaries. A federal ban would terminate this initiative before launch, according to CMS officials who spoke on background to industry publications.

Financial markets have already reacted. Publicly traded hemp companies saw share prices decline 30-45% following initial reports of the proposed ban. Private equity firms that invested heavily in the CBD sector between 2019 and 2024 face potential write-downs. Agricultural lenders in Kentucky, North Carolina, and Oregon—states with concentrated hemp farming—have begun reassessing loan portfolios.

Background and History

The 2018 Farm Bill and Hemp Legalization

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed hemp from Schedule I of the Controlled Substances Act and legalized cultivation of cannabis plants containing 0.3% delta-9 THC or less. The bill, championed by Senate Majority Leader Mitch McConnell of Kentucky, represented a watershed moment for American agriculture. Hemp had been effectively banned since the Marihuana Tax Act of 1937, with only a brief exception for World War II production.

The 2018 Farm Bill defined hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition appeared in 7 U.S.C. § 1639o and explicitly removed hemp from the definition of marijuana under 21 U.S.C. § 802(16).

The legislation transferred primary regulatory authority from the DEA to the U.S. Department of Agriculture. States were required to submit hemp production plans to USDA for approval, establishing testing protocols, disposal procedures for non-compliant crops, and licensing requirements for cultivators. The FDA retained authority over hemp-derived products intended for human or animal consumption.

The CBD Boom: 2019-2023

Following legalization, the CBD market exploded. Industry analysts estimated the market grew from $600 million in 2018 to $4.6 billion in 2021. Products ranged from CBD isolate tinctures and full-spectrum oils to topical creams, pet treats, and beverage additives. Major retailers including CVS, Walgreens, and Kroger began carrying CBD products in 2019. Online marketplaces saw thousands of new CBD brands launch.

The FDA, however, maintained that CBD could not be legally added to food or marketed as a dietary supplement because it was the active ingredient in Epidiolex, an FDA-approved drug for epilepsy. Despite this position, the agency largely declined to enforce against CBD products, issuing only occasional warning letters to companies making egregious health claims. This created a gray market where products were widely available but technically violated federal food and drug law.

The Intoxicating Cannabinoid Problem: 2020-2025

The emergence of intoxicating hemp-derived cannabinoids like delta-8 THC, delta-10 THC, THC-O, and THCA flower exposed a loophole in the 2018 Farm Bill that lawmakers had not anticipated. Manufacturers discovered they could convert CBD into delta-8 THC through chemical synthesis, creating a psychoactive product that technically met the legal definition of hemp because the final product contained less than 0.3% delta-9 THC.

Delta-8 products appeared in gas stations, convenience stores, and smoke shops across the country, including in states that had not legalized recreational cannabis. The products were marketed with minimal regulation, often without child-resistant packaging or potency testing. Poison control centers reported increased calls related to delta-8 consumption, particularly among children who consumed gummy products.

THCA flower presented a different challenge. THCA (tetrahydrocannabinolic acid) is the non-psychoactive precursor to delta-9 THC found in raw cannabis. When heated through smoking or vaping, THCA converts to delta-9 THC. Cultivators began selling high-THCA hemp flower that was chemically identical to marijuana but tested below 0.3% delta-9 THC in its raw form. Consumers could purchase what was effectively marijuana under the guise of legal hemp.

Between 2021 and 2024, at least 15 states enacted their own restrictions on delta-8 and other intoxicating hemp cannabinoids. These included Colorado, Montana, Oregon, Alaska, and Arkansas. The patchwork of state laws created compliance challenges for interstate commerce and highlighted the need for federal clarification.

Federal Response and the Proposed Ban

In March 2025, the DEA published an Advance Notice of Proposed Rulemaking (ANPRM) seeking public comment on how to address intoxicating hemp-derived cannabinoids. The agency received over 43,000 comments during the 90-day comment period. Industry groups urged targeted regulation of synthetic cannabinoids while preserving the legal status of traditional CBD products. Law enforcement organizations and some public health advocates called for broader restrictions.

On February 12, 2026, the DEA published a Notice of Proposed Rulemaking (NPRM) that went further than many observers expected. The proposed rule would redefine hemp to exclude any cannabis plant or product containing "total THC" above 0.3%, where total THC includes delta-9 THC, delta-8 THC, delta-10 THC, THCA, and other THC isomers. The rule would also prohibit chemical synthesis of cannabinoids from hemp-derived CBD.

Critically, the proposed rule's definition of "total THC" created uncertainty about CBD products. Many full-spectrum CBD oils contain trace amounts of THCA or other cannabinoids that could push total THC above the 0.3% threshold even if delta-9 THC remains below that level. The rule text did not clearly exempt traditional CBD products, leading industry lawyers to warn that the ban could inadvertently criminalize the entire CBD market.

The comment period for the NPRM closed on April 30, 2026, with over 87,000 submissions. The DEA must now review comments and publish a final rule, which could take six to eighteen months. Any final rule would likely face immediate legal challenges.

Key Players

Drug Enforcement Administration

The DEA holds primary authority over controlled substance scheduling and has driven the proposed hemp ban as a response to intoxicating cannabinoid proliferation. Administrator Anne Milgram has publicly stated that the agency views delta-8 THC and similar products as "end runs around the Controlled Substances Act" that create public health risks. The DEA's Diversion Control Division drafted the proposed rule in coordination with the Office of the Attorney General.

DEA officials have emphasized that the rule targets intoxicating products, not traditional CBD. However, the agency has not provided clear guidance on how manufacturers can ensure compliance or what testing protocols would be required to verify total THC levels. This ambiguity has fueled industry concerns about overreach.

Food and Drug Administration

The FDA shares regulatory responsibility for hemp-derived products intended for human consumption. The agency has long maintained that CBD cannot be legally sold as a dietary supplement or food additive, but enforcement has been minimal. In the context of the proposed DEA rule, the FDA has indicated it would develop a regulatory pathway for CBD products if they remain legal under the Controlled Substances Act.

FDA Commissioner Robert Califf stated in congressional testimony in March 2026 that the agency supports "science-based regulation of CBD that protects consumers while allowing access to products with demonstrated safety." The FDA has called for mandatory product registration, potency testing, and contaminant screening for any CBD products that remain legal after the DEA rule takes effect.

U.S. Department of Agriculture

The USDA oversees hemp cultivation through its domestic hemp production program established under the 2018 Farm Bill. The department has licensed over 17,000 hemp producers across 47 states. USDA officials have expressed concern that the DEA rule could devastate American hemp farmers who have invested millions in infrastructure, genetics, and compliance systems.

Agriculture Secretary Tom Vilsack sent a letter to the DEA in March 2026 urging the agency to "carefully consider the economic impact on rural America" and to provide a clear safe harbor for non-intoxicating hemp products. The USDA has not taken a formal position on the proposed rule but has indicated it would need to revise its hemp regulations to align with any DEA changes.

Hemp Industry Groups

The U.S. Hemp Roundtable, Vote Hemp, and the Hemp Industries Association have led industry opposition to the proposed ban. These organizations represent farmers, processors, and manufacturers across the supply chain. They have argued that the DEA rule is overly broad, economically destructive, and legally questionable.

Jonathan Miller, general counsel for the U.S. Hemp Roundtable, said the proposed rule "would undo six years of legal hemp commerce and harm millions of consumers who rely on CBD for wellness." The industry has proposed alternative regulatory frameworks that would specifically target synthetic intoxicating cannabinoids while preserving traditional hemp products.

State Regulators

State departments of agriculture and cannabis control boards have taken varied positions. States with established adult-use cannabis programs, such as California, Colorado, and Michigan, have generally supported federal action to close the intoxicating hemp loophole, viewing it as unfair competition for licensed cannabis businesses that face strict testing and taxation requirements.

States with significant hemp agriculture, including Kentucky, North Carolina, and Tennessee, have opposed the ban. Kentucky Agriculture Commissioner Jonathan Shell called the proposed rule "a betrayal of the promise made to hemp farmers in the 2018 Farm Bill."

Consumer and Patient Advocacy Groups

Organizations representing veterans, chronic pain patients, and CBD consumers have mobilized against the ban. The Veterans Cannabis Coalition submitted comments arguing that many veterans use CBD to manage service-related injuries and mental health conditions. The American Chronic Pain Association noted that CBD offers an alternative to opioids for some patients.

Public health organizations have been divided. The American Medical Association has called for more research on CBD safety and efficacy but has not taken a position on the DEA rule. The American Academy of Pediatrics has supported restrictions on intoxicating hemp products marketed to youth.

Legal and Regulatory Framework

Controlled Substances Act Authority

The DEA derives its authority to regulate hemp from the Controlled Substances Act, 21 U.S.C. § 801 et seq., which grants the Attorney General (acting through the DEA) power to schedule substances based on abuse potential, medical use, and safety. The 2018 Farm Bill amended the definition of marijuana in 21 U.S.C. § 802(16) to exclude hemp, but it did not remove the DEA's authority to regulate cannabis derivatives or synthetic cannabinoids.

The proposed rule relies on the DEA's authority under 21 U.S.C. § 811 to establish scheduling criteria and under 21 U.S.C. § 812 to maintain the drug schedules. The agency argues that cannabinoids meeting the definition of THC fall under Schedule I unless they meet the statutory hemp exemption, and that the exemption should be narrowly construed to exclude intoxicating products.

Administrative Procedure Act Requirements

The DEA must comply with the Administrative Procedure Act, 5 U.S.C. § 553, in promulgating the hemp rule. This requires publication of the proposed rule in the Federal Register, a public comment period of at least 30 days, consideration of public comments, and publication of a final rule with a statement of basis and purpose.

Industry groups are likely to challenge any final rule under the APA, arguing that the DEA acted arbitrarily and capriciously by failing to adequately consider economic impacts, by not providing clear compliance pathways, or by exceeding its statutory authority. Courts review agency rules under the standard established in Motor Vehicle Manufacturers Association v. State Farm Mutual Automobile Insurance Co., requiring a reasoned explanation for agency decisions.

Congressional Authority and the Farm Bill

The 2018 Farm Bill's hemp provisions were enacted under Congress's authority to regulate interstate commerce under Article I, Section 8 of the Constitution. The bill explicitly legalized hemp and hemp-derived products, creating tension with the DEA's proposed restrictions. Industry lawyers argue that the DEA cannot use its Controlled Substances Act authority to effectively nullify a congressional determination that hemp is legal.

The counter-argument is that Congress legalized hemp but did not legalize all possible hemp-derived products, particularly those created through chemical synthesis or those that are intoxicating. The DEA maintains it is implementing, not contradicting, congressional intent.

The 2024 Farm Bill, currently pending reauthorization, could resolve this conflict. Several proposed amendments would explicitly address intoxicating hemp cannabinoids, either by banning them specifically or by creating a regulatory framework for their sale. However, Farm Bill negotiations have stalled over unrelated agricultural policy disputes, leaving the hemp industry in regulatory limbo.

Federalism and State Law Conflicts

The proposed federal ban would create conflicts with state hemp laws in states that have chosen to allow intoxicating hemp products or that have built regulatory frameworks around CBD. Under the Supremacy Clause of the Constitution, federal law preempts conflicting state law. However, states retain authority to impose stricter regulations than federal law requires.

If the DEA bans a product at the federal level, states cannot legalize it for purposes of federal law, but they can choose not to enforce federal prohibitions with state resources. This is the model that has allowed state cannabis legalization to proceed despite federal prohibition. However, it would create significant practical problems for hemp businesses, which would remain subject to federal prosecution and would be unable to access banking services or interstate commerce.

State-by-State Breakdown

Kentucky

Kentucky has the largest hemp acreage in the United States with over 30,000 licensed acres and has built a significant portion of its agricultural economy around hemp since 2018. The state allows CBD products and has not banned delta-8 or other intoxicating hemp cannabinoids at the state level. Kentucky hemp farmers have invested over $400 million in processing facilities, genetics programs, and cultivation infrastructure. A federal ban would devastate the state's rural economy, according to the Kentucky Hemp Association. The state has not indicated whether it would continue to allow hemp cultivation if the federal ban takes effect, creating uncertainty for the 2027 planting season.

North Carolina

North Carolina is the second-largest hemp producer with approximately 18,000 licensed acres. The state has developed a robust hemp processing sector, with over 200 licensed processors producing CBD isolate, distillate, and finished products. North Carolina banned delta-8 THC in 2022 but continues to allow traditional CBD products. State agriculture officials have lobbied Congress to intervene and prevent the DEA ban. The North Carolina Farm Bureau has called the proposed rule "an existential threat to a nascent agricultural industry."

Colorado

Colorado legalized adult-use cannabis in 2012 and has taken a more restrictive approach to hemp than other states. The state banned delta-8 THC and other intoxicating hemp cannabinoids in 2021, requiring that such products be sold only through licensed cannabis dispensaries where they are subject to testing and taxation. Colorado has supported federal action to close the intoxicating hemp loophole, viewing it as necessary to protect the integrity of its regulated cannabis market. However, Colorado hemp farmers who produce CBD for non-intoxicating products have opposed the federal ban.

California

California, despite having the largest legal cannabis market in the country, also has a significant hemp industry focused on CBD production. The state banned delta-8 and similar products in 2021 through emergency regulations. California has approximately 12,000 licensed hemp acres and a well-developed CBD manufacturing sector. State officials have supported targeted federal restrictions on intoxicating hemp products but have urged the DEA to preserve legal pathways for traditional CBD. The California Hemp Association has warned that a broad federal ban would eliminate thousands of jobs in a state already struggling with cannabis industry consolidation.

Oregon

Oregon banned delta-8 THC in 2021 and requires that hemp-derived intoxicating products be sold through licensed cannabis retailers. The state has about 8,000 licensed hemp acres, down from a peak of 63,000 acres in 2019 before a market glut crashed prices. Oregon hemp farmers have pivoted toward CBD production for national markets. A federal ban would eliminate this market, potentially forcing many remaining farmers out of hemp entirely. The Oregon Department of Agriculture has called for federal clarity but has not taken a formal position on the DEA proposal.

New York

New York legalized adult-use cannabis in 2021 and has moved to restrict intoxicating hemp products. The state's Cannabis Control Board issued regulations in 2023 requiring that any hemp product containing more than trace amounts of THC be sold through licensed cannabis dispensaries. New York has a growing hemp industry with approximately 5,000 licensed acres, primarily focused on CBD production. The state has supported federal regulation of intoxicating hemp but has urged preservation of the CBD market. New York's large consumer base makes it a critical market for CBD manufacturers.

Florida

Florida has not legalized adult-use cannabis but has a large medical marijuana program and a thriving hemp industry. The state has approximately 7,000 licensed hemp acres and has not banned delta-8 or other intoxicating hemp cannabinoids. Florida's hemp market is worth an estimated $800 million annually. State agriculture officials have opposed the federal ban, arguing it would harm Florida farmers and businesses. However, Florida's cannabis industry has supported federal restrictions, viewing intoxicating hemp as unfair competition for licensed medical marijuana operators.

Texas

Texas has not legalized recreational cannabis but has a large hemp industry with approximately 9,000 licensed acres. The state initially moved to ban delta-8 THC in 2021, but a court ruling found the ban inconsistent with the state's hemp law, leaving delta-8 in legal limbo. Texas allows CBD products and has a significant manufacturing sector. A federal ban would impact thousands of Texas businesses and farmers. The Texas Hemp Coalition has actively lobbied against the DEA proposal, while law enforcement organizations in the state have supported it.

Market and Business Implications

Impact on Multi-State Operators

The federal hemp ban would create both challenges and opportunities for cannabis multi-state operators (MSOs) that have largely avoided the hemp market. Companies like Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs operate licensed cannabis dispensaries in multiple states and have viewed intoxicating hemp products as unfair competition. These MSOs have supported federal restrictions that would channel intoxicating cannabinoid sales through regulated cannabis channels.

However, a broad ban that includes traditional CBD could eliminate a potential future revenue stream. Several MSOs had been exploring CBD product lines for national distribution once federal regulations clarified. Curaleaf, for example, acquired CBD brand Select in 2020 with plans for eventual national expansion. A federal ban would foreclose this strategy.

The ban could also impact MSO wholesale operations. Some licensed cannabis processors in states like California and Colorado produce CBD products for out-of-state sale. These operations would need to shut down or pivot to THC products for in-state sale only.

Hemp Farmer Economics

Hemp cultivation economics have been challenging even without a federal ban. After the 2018 Farm Bill, a rush of new farmers entered the market, creating oversupply and crashing prices. CBD biomass that sold for $40-50 per pound in 2019 fell to $3-5 per pound by 2022. Many farmers exited the industry, and total U.S. hemp acreage declined from 146,000 acres in 2019 to approximately 54,000 acres in 2025.

Farmers who remained in the industry invested in genetics, equipment, and processing relationships to produce higher-quality CBD or to pivot to hemp grain and fiber. A federal ban would eliminate the CBD market entirely, leaving only industrial hemp applications like textiles, building materials, and animal bedding. These markets are far smaller and less developed than the CBD market, and prices are significantly lower.

The economic impact would be concentrated in rural areas of Kentucky, North Carolina, Tennessee, Oregon, and Colorado. These regions have limited alternative cash crops, and hemp provided a higher-value option than traditional commodities like tobacco or wheat. Agricultural economists estimate that a federal hemp ban could eliminate $2-3 billion in annual farm gate revenue.

CBD Manufacturing and Retail

The CBD manufacturing sector includes extraction facilities, formulation labs, and white-label producers that supply finished products to brands. This sector has invested hundreds of millions of dollars in equipment, facilities, and compliance systems. A federal ban would render much of this infrastructure worthless, as it is purpose-built for cannabinoid processing and cannot easily be repurposed.

Retail impacts would extend across multiple channels. Specialty CBD stores would face closure. Health food stores, vitamin shops, and natural product retailers that added CBD sections would lose a significant product category. Major pharmacy chains like CVS and Walgreens, which began carrying CBD topicals and tinctures in 2019-2020, would need to remove products from thousands of store locations.

Online CBD sales, which account for approximately 40% of the market, would cease entirely. E-commerce platforms including Amazon (which allows CBD topicals but not ingestibles), Shopify stores, and dedicated CBD marketplaces would need to delist products and refund orders.

Investment and Capital Markets

The CBD sector attracted significant venture capital and private equity investment between 2018 and 2022. Firms including Gotham Green Partners, Poseidon Asset Management, and Tuatara Capital deployed hundreds of millions into hemp cultivation, processing, and branded product companies. A federal ban would result in substantial write-downs and losses for these investors.

Publicly traded hemp companies have already seen significant stock price declines. Charlotte's Web Holdings, one of the largest CBD brands, saw its stock price fall 38% in the week following publication of the DEA's proposed rule. CV Sciences, another public CBD company, declined 42%. These companies have limited options to pivot their business models and may face delisting or bankruptcy if the ban takes effect.

The ban would also impact cannabis MSOs that had planned to enter the CBD market. Several companies had allocated capital for CBD acquisitions or product development. These plans would be abandoned, potentially affecting company valuations and investor returns.

Banking and Financial Services

Hemp businesses have enjoyed access to traditional banking services that remain unavailable to cannabis companies due to federal prohibition. A federal hemp ban would terminate this access, forcing hemp companies into the same cash-based operations that plague the cannabis industry. Banks would be required to close hemp business accounts to avoid violating federal money laundering laws under 18 U.S.C. § 1956.

Payment processors including Visa, Mastercard, and PayPal would prohibit hemp transactions. E-commerce would become nearly impossible without credit card processing. Hemp businesses would lose access to business loans, lines of credit, and merchant services.

What Experts Say

Legal scholars have questioned whether the DEA has authority to effectively overturn the 2018 Farm Bill's hemp legalization through administrative rulemaking. Professor Robert Mikos of Vanderbilt Law School, an expert on federalism and drug policy, said the proposed rule "raises serious questions about the limits of agency authority when Congress has spoken clearly on a topic." Mikos noted that courts generally defer to agencies on technical matters but are more skeptical when agencies appear to contradict congressional intent.

Agricultural economists have warned of severe rural economic impacts. Dr. Tyler Mark, an agricultural economist at the University of Kentucky, estimated that a federal hemp ban could eliminate 15,000-20,000 jobs in Kentucky alone and reduce state agricultural revenue by $450-600 million annually. Mark said many hemp farmers lack viable alternative crops and could face farm foreclosures if hemp markets disappear.

Public health researchers have expressed mixed views. Dr. Yasmin Hurd, director of the Addiction Institute at Mount Sinai, has supported restrictions on intoxicating hemp products, particularly delta-8 THC, citing lack of safety testing and concerns about youth access. However, Hurd has also noted that CBD appears to have a favorable safety profile based on available research and that eliminating access could harm patients who benefit from it.

Industry consultants have focused on the practical impossibility of compliance. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, said the proposed rule's "total THC" standard would require testing methods that are not widely available and would create false positives due to the presence of naturally occurring cannabinoid precursors. Miller argued that the rule is "unworkable as written and would criminalize products that have been legal for six years."

Cannabis policy advocates have been divided. The National Organization for the Reform of Marijuana Laws (NORML) has opposed the hemp ban, arguing that it represents a step backward for cannabis policy reform. However, some state-level legalization advocates have supported restrictions on intoxicating hemp products, viewing them as undermining regulated cannabis markets and creating public safety risks.

What's Next

The DEA must now review the 87,000 public comments submitted during the comment period that closed on April 30, 2026, and publish a final rule, likely in late 2026 or early 2027. The agency could modify the proposed rule in response to comments, narrow its scope to target only synthetic intoxicating cannabinoids, or proceed with the rule as proposed. Any final rule must include a statement explaining how the agency considered public input and addressed major concerns raised during the comment period.

If the DEA publishes a final rule that bans or severely restricts CBD products, legal challenges are certain. Industry groups have already retained law firms specializing in administrative law and are prepared to file suit in federal court. Likely venues include the U.S. Court of Appeals for the D.C. Circuit, which has jurisdiction over challenges to federal agency actions, or district courts in states with significant hemp industries.

Litigation could take 18-36 months to resolve. Courts would consider whether the DEA exceeded its statutory authority, whether the rule is arbitrary and capricious under the Administrative Procedure Act, and whether the agency adequately considered economic and social impacts. Industry groups may also seek preliminary injunctions to prevent the rule from taking effect while litigation proceeds.

Congressional intervention remains possible. Senator Rand Paul of Kentucky and Representative James Comer, also of Kentucky, have introduced legislation to explicitly protect hemp-derived CBD from DEA scheduling. The Hemp and Hemp-Derived CBD Consumer Protection Act would amend the Controlled Substances Act to clarify that hemp and hemp-derived products meeting the 2018 Farm Bill definition are not controlled substances. However, the bill faces uncertain prospects in a divided Congress.

The 2024 Farm Bill reauthorization, currently stalled in conference committee, could also address the issue. Several proposed amendments would create a regulatory framework for hemp-derived cannabinoids, establishing potency limits, age restrictions, and labeling requirements while preserving legal access. However, Farm Bill negotiations have been complicated by disputes over commodity support programs and conservation funding, and hemp provisions may not be prioritized.

State responses will vary. States with adult-use cannabis programs may welcome federal restrictions that eliminate hemp competition for licensed cannabis businesses. States with significant hemp agriculture may attempt to preserve state-level legality, though this would not protect hemp businesses from federal prosecution or restore access to banking and interstate commerce.

The Medicare CBD pilot program, which had been scheduled to launch in January 2027, has been suspended pending resolution of the DEA rule. CMS officials have indicated the program cannot proceed if CBD products are federally illegal, regardless of potential therapeutic benefits. This represents a significant setback for efforts to integrate cannabis-derived products into mainstream healthcare.

Industry consolidation is likely regardless of the rule's outcome. Smaller CBD brands and manufacturers are already exiting the market due to regulatory uncertainty. Larger companies with diversified product lines or access to capital may acquire distressed assets at discounted prices. Some hemp businesses may attempt to pivot to state-licensed cannabis operations in states where they have existing facilities, though this would require new licenses and compliance with state regulations.

The broader cannabis policy landscape will also influence outcomes. If federal cannabis legalization or rescheduling occurs before the hemp ban takes effect, it could render the entire debate moot by creating a unified regulatory framework for all cannabis products. However, comprehensive federal cannabis reform has stalled repeatedly in Congress, and prospects for near-term action remain uncertain.

Further Reading

• Agriculture Improvement Act of 2018 (2018 Farm Bill), Public Law 115-334, full text available at https://www.congress.gov/bill/115th-congress/house-bill/2
• DEA Notice of Proposed Rulemaking on Hemp-Derived Cannabinoids, Federal Register Vol. 91, No. 32 (February 12, 2026), available at https://www.federalregister.gov
• USDA Domestic Hemp Production Program regulations, 7 CFR Part 990, available at https://www.ams.usda.gov/rules-regulations/hemp
• Controlled Substances Act, 21 U.S.C. § 801 et seq., full text at https://www.deadiversion.usdoj.gov/21cfr/21usc/
• U.S. Hemp Roundtable comment letter to DEA (April 2026), available at https://www.hempsupporter.com
• Congressional Research Service, "The 2018 Farm Bill and Hemp Legalization" (updated 2025), available at https://crsreports.congress.gov
• FDA statement on regulation of cannabis and cannabis-derived products, available at https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products
• National Conference of State Legislatures, "State Industrial Hemp Statutes," available at https://www.ncsl.org/agriculture-and-rural-development/state-industrial-hemp-statutes

Update — May 24, 2026: North Carolina Hemp Industry Confronts Federal Ban Deadline

North Carolina's hemp-derived cannabinoid industry faced an existential crisis as the federal ban on intoxicating hemp products approached its enforcement deadline. The state's hemp businesses, which generated approximately $2.8 billion in annual economic activity, prepared for widespread closures as the Drug Enforcement Administration finalized rules classifying delta-8 THC, delta-10 THC, and other semi-synthetic cannabinoids as Schedule I controlled substances. According to the North Carolina Industrial Hemp Association, more than 3,400 retail locations across the state sold hemp-derived products, employing an estimated 18,000 workers in manufacturing, distribution, and retail operations.

State legislators scrambled to address the regulatory vacuum left by federal action. North Carolina Senate Bill 711, introduced May 19, proposed a state-regulated hemp cannabinoid market with testing requirements, age restrictions, and licensing fees, but the bill remained stalled in committee as the federal deadline loomed. Hemp business owners reported inventory losses exceeding $450 million statewide, with products containing now-banned compounds becoming unsellable overnight. The Charlotte-based Hemp Industry Coalition filed an emergency petition with the Fourth Circuit Court of Appeals seeking a temporary injunction, arguing the DEA exceeded its statutory authority under the 2018 Farm Bill.

Financial institutions accelerated account closures for hemp businesses, citing federal banking compliance concerns. Wilmington-based processor Carolina Hemp Company reported that Wells Fargo, Bank of America, and Truist all terminated merchant services between May 15 and May 22, forcing the company to operate on a cash-only basis. Industry representatives estimated that 62% of North Carolina hemp retailers would cease operations within 30 days absent state intervention or federal enforcement delays, with rural counties facing disproportionate economic impact due to limited alternative employment opportunities in agricultural communities.

The crisis extended beyond retail operations to affect North Carolina's agricultural sector. Hemp farmers who cultivated crops specifically for cannabinoid extraction faced complete market collapse, with approximately 8,700 acres of licensed hemp cultivation at risk of abandonment. The North Carolina Department of Agriculture reported that hemp permit applications for the 2026 growing season dropped 73% compared to 2025 levels, signaling long-term industry contraction regardless of potential state regulatory frameworks.